FDA and HHS submitted a peptide policy for White House review, outlining an interim access approach for compounding using certain peptides. Separately, the update package also covered label expansion news tied to Enspryng, alongside other pipeline and company-specific items. The interim policy submission signals ongoing regulatory effort to balance patient access with safety and oversight concerns in compounding, an area that has drawn heightened scrutiny as peptide demand has expanded. For developers and compounding stakeholders, the near-term procedural path through the White House office suggests that guidance could shift sooner than typical rulemaking cycles.